Promising novel siRNA for the treatment of hypertension

Nature Reviews Cardiology, Published online: 31 July 2023; doi:10.1038/s41569-023-00916-9Patients with hypertension who receive a single subcutaneous dose of zilebesiran, a novel small-interfering RNA that inhibits hepatic angiotensinogen synthesis, have reductions in serum angiotensinogen levels and 24-h ambulatory blood pressure that last for up to 24 weeks, according to a phase I study.
Source: Nature Reviews Cardiology - Category: Cardiology Authors: Source Type: research